|
|
|
19.05.26 - 21:15
|
VahatiCor ernennt Dr. Harry D. Rowland zum Chief Executive Officer (Business Wire)
|
|
|
Der Mitbegründer und ehemalige CEO von Endotronix wechselt zu VahatiCor, während das Unternehmen die Entwicklung des A-FLUX Reducer System® sowie die SERRA-I-Studie zur frühen Machbarkeit vorantreibtSANTA CLARA, Kalifornien--(BUSINESS WIRE)--VahatiCor, Inc., ein Medizintechnikunternehmen, das interventionelle Therapien für die koronare mikrovaskuläre Dysfunktion (CMD) entwickelt, gab heute die Ernennung von Harry D. Rowland, Ph.D. zum Chief Executive Officer bekannt.
Rowland war zuvor als Chief Executive Officer und President von Endotronix tätig, wo er die Entwicklung und Vermarktung des Cordella™-Lungenarteriensensors und des Herzinsuffizienz-Systems leitete. Unter seiner Führung beschaffte Endotronix über 150 Millionen US-Dollar und wuchs auf mehr als 150 Mitarbeiter an. Darüber hinaus leitete er die zulassungsrelevante PROACTIVE-HF-Studie von der Durchführung über die FDA-Zulassung bis hin zur Markteinführung. Nach der Übernahme durch Edwards Lifesciences im Jahr 2024 blieb Rowland im ...
|
|
|
|
|
|
|
18.05.26 - 08:03
|
Tulyp Medical Appoints Industry Veteran Steve Motes as CEO to Lead Next Phase of Growth in the US (Business Wire)
|
|
|
Steve Motes brings deep expertise in Mechanical Circulatory Support (MCS) and early-stage company leadership
Company backed by Sofinnova Partners and leading medtech entrepreneurs and cardiologists
PARIS & DALLAS--(BUSINESS WIRE)--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company's first-in-human study.
Steve joins Tulyp with more than 30 years of experience in the medical device industry, primarily focused on cardiovascular technologies. He has held leadership roles at Draeger, Medtronic (formerly Somanetics), Edwards Lifesciences, and Abbott. At Abbott, he contributed to the launch of the HeartMate 3 LVAD system and played a key role in expanding the company's ECMO business. More recently, he has served as CEO of several early-stage companies, including those in the MCS space.
“I am thrilled to join Tulyp at...
|
|
|
18.05.26 - 08:03
|
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer (Business Wire)
|
|
|
Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility studySANTA CLARA, Calif.--(BUSINESS WIRE)--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer.
Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones.
"Harry has led a medical company through this arc before. He took Endotronix ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 22:51
|
Edwards Lifesciences Announces Appointment of CFO (Business Wire)
|
|
|
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role.
Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planning, reporting and operational finance across a complex, global business. Prior to Viatris, she was a managing director in healthcare investment banking at Citigroup Global Markets, and earlier in her career held senior leadership roles in healthcare investment banking at Goldman Sachs. Mistras brings decades of healthcare leadership experience helping guide corporate boards and executive teams on corporate finance, strategy and investor relations. She holds a bachelor's degree in international studies from th...
|
|
|
02.05.26 - 17:51
|
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences′ Resilia Tissue (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.
As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards' RESILIA tissue and its role in lifetime management for patients with aortic stenosis. To date, more than 500,000 patients worldwide have been treated with Edwards' surgical and transcatheter innovations featuring RESILIA tissue.
At 10 years, COMMENCE trial data showed that patients treated with Edwards' surgical valves featuring RESILIA tissue experienced:
97.9% freedom from structural valve deterioration (SVD)
97.8% freedom from reoperation due to SVD
98.6...
|
|
|
|
|
|
|
|
|
|
|
23.04.26 - 23:06
|
Edwards Lifesciences Corp. Q1 Income Rises (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) released a profit for its first quarter that Increases, from the same period last yearThe company's earnings came in at $380.7 million, or $0......
|
|
|
|
|
23.04.26 - 22:21
|
Edwards Lifesciences Reports First Quarter Results (Business Wire)
|
|
|
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026.
Highlights and Outlook
Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7%
Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0%
Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies
Q1 EPS of $0.661; adjusted2 EPS of $0.781
Raising FY 2026 constant currency2 sales growth guidance to 9% to 11% from 8% to 10%
Raising FY 2026 adjusted2 EPS guidance midpoint; new range of $2.95 to $3.05 from $2.90 to $3.05
Renewed clinical focus on proactive disease management with differentiated SAPIEN TAVR
Completed $500 million Accelerated Share Repurchase
“Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1, achieving 12.7% sales growth, which reflects the impact and durability of our focused strategy. We remain dedicated to solving larg...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
